Innate Pharma S.A. (EPA:IPH)
1.780
+0.256 (16.80%)
Last updated: Nov 10, 2025, 2:50 PM CET
Innate Pharma Revenue
Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.
Revenue (ttm)
12.64M
Revenue Growth
-62.60%
P/S Ratio
11.12
Revenue / Employee
72.62K
Employees
181
Market Cap
140.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
Innate Pharma News
- 9 hours ago - Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacutamab Trial - GuruFocus
- 14 hours ago - Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL - Business Wire
- 5 days ago - Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates - Business Wire
- 12 days ago - Innate Pharma (IPHA) Upgraded to Buy by HC Wainwright & Co. | IPHA Stock News - GuruFocus
- 12 days ago - This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
- 12 days ago - BTIG Reiterates Buy Rating for Innate Pharma (IPHA) with $8 Target | IPHA Stock News - GuruFocus
- 12 days ago - Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript - Seeking Alpha
- 12 days ago - Innate Pharma S.A. (IPHA) Analyst/Investor Day - Slideshow - Seeking Alpha